Bruker Advances NMR Magnet Portfolio, Innovates in Industrial Solutions
Bruker Corporation recently showcased its latest innovations in NMR spectroscopy at the Experimental Nuclear Magnetic Resonance Conference (ENC 2023). The highlight is the launch of the Ascend Evo 400, a new 400 MHz NMR magnet with a liquid helium hold-time of one year. This advancement reduces ownership costs and enhances operational convenience.
The Ascend Evo 1.0 GHz system, featuring a 65% reduction in liquid helium consumption, is utilized in prestigious labs like the RIKEN Center in Japan. The release also discusses the HelioSmart-R system, which recovers helium gas, and the new Fourier 80 platform for battery and pharmaceutical research.
Bruker emphasizes its commitment to sustainability and advancing cleantech research, highlighting collaborations with key industry players.
- Launch of the Ascend Evo 400 NMR magnet with a one-year helium hold-time reduces operational costs.
- 65% reduction in helium consumption for the Ascend Evo 1.0 GHz system.
- Successful installations of the HelioSmart-R recovery solution in major pharma labs.
- New Fourier 80 platform enhances capabilities for battery and pharmaceutical research.
- Partnerships with leading institutions like Dragonfly Energy for advancing battery technology.
- None.
Advancements in NMR enable deeper insights into life science, drug discovery, and cleantech
ASILOMAR, Calif.--(BUSINESS WIRE)-- At the Experimental Nuclear Magnetic Resonance Conference (ENC 2023), Bruker announces innovations for NMR spectroscopy in life science, pharma, and cleantech research to enable discoveries in functional structural biology, drug discovery, and battery research.
Ascend Evo 400 NMR magnet with a liquid helium hold-time of one year (Photo: Business Wire)
Bruker launches the Ascend Evo 400 new standard 400 MHz NMR magnet with a liquid helium hold-time of one year to reduce cost of ownership and enhance operational convenience. This novel magnet also has improved field homogeneity with new cryogenic shimming technology originally developed for ultra-high field magnets, in order to make sample shimming and operation even easier.
This 400 MHz innovation joins the Ascend Evo 1.0 GHz with ~
Bruker offers helium recovery with its HelioSmart-R, a compact system to collect helium gas boil-off from magnets. Bruker announces successful installations of the HelioSmart-R recovery solution in pharma labs of Merck in
The new HelioSmart-L solution for liquefaction, collects and liquifies helium gas boil-off from installed NMR magnets with over
At ENC 2023, Bruker also introduces new industrial and pharmaceutical capabilities for the Fourier™ 80 benchtop FT-NMR platform. The new Fourier 80 X-optimized 1H/7Li system will be an essential tool for battery research to study atomic-level properties of lithium-containing materials critical for more efficient batteries.
Dr.
The new Fourier 80 1H/13C/19F system advances pharmaceutical research. 19F NMR is a powerful tool in drug discovery and development that provides information about chemical structure, formulation, safety, and toxicity of fluorinated drug molecules. This aids in optimizing efficacy, safety, and formulation of drug candidates.
Chemical engineer
Dr.
To learn about Bruker at ENC, please visit: https://www.bruker.com/en/news-and-events/events/enc.html
About
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230417005183/en/
Investor Contact:
Sr. Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com
Media Contact:
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com
Source:
FAQ
What innovations did Bruker announce at ENC 2023?
How does the Ascend Evo 400 improve operational efficiency?
What is the helium consumption reduction for Bruker's Ascend Evo 1.0 GHz system?
What sustainability initiative did Bruker implement?